Login to Your Account



Pozen Licenses Migraine Drug To GSK In Potential $160M Deal

By Aaron Lorenzo


Friday, June 13, 2003
Pozen Inc. could garner up to at least $160 million after entering a deal with GlaxoSmithKline plc surrounding a migraine treatment. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription